One thing that we did early on was to set up new mechanisms to work in a pandemic, many of which, surprisingly, weren't set up before. One of them was a standardized indemnification liability agreement. We got all of the manufacturers to agree to that. That has now been approved by all of the countries that are receiving COVAX doses. When the doses that Canada donates are transferred to the COVAX facility, they get covered by those indemnification and liability agreements.
One other thing we've done, which has really been an innovation, is to also have a no-fault compensation scheme set up for all these countries. In the case of severe disease or death from vaccine-related effects, that allows countries to go ahead and receive a certain amount of financing that is available. That is funded by a certain price on each dose of vaccine that is part of the COVAX facility. That covers both the doses that COVAX purchases as well as the doses that are donated through the COVAX facility.